ClinicalTrials.gg
RecruitingNCT05008081Updated May 22, 2026

The CATALINA Study

An observational study in Chronic Obstructive Pulmonary Disease Exacerbation, sponsored by Wim Janssens. Recruiting at 22 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Wim Janssens · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany — 33 open to participants now, 46 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · Germany.

Planned enrollment
20th of 96
1,000 · median 178
Started
2022
with 16 others
Observational
97 of 539
11 open now
Primary completion
2027-03
later than 20 of 45 live
Registered
463rd of 539
by date

Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, this one is the 20th largest by planned enrollment of the 96 observational ones that give a count, is one of 17 that started in 2022, is one of 97 observational ones, reaches primary completion later than 20 of the 45 other live ones, and was the 463rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

33 of the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, or all of them as a file.
02

Study summary

The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.

Read the detailed description

The initial objective is to recruit 1000 patients hospitalised for an acute COPD exacerbation by the end of CICERO's first lifecycle (3 years), from whom 1 year follow-up data and biological samples will be collected. By doing so, CICERO aims to develop a comprehensive European COPD patient data- and biobank phenotyped in relation to the exacerbation, to support the development of future EU-wide clinical intervention trials in COPD for specific patient subgroups, as well as new prognostication tools for COPD exacerbations.

The clinical data and biological samples will be obtained during 6 scheduled study visits, during the hospitalization period of the index acute exacerbation as well as the outpatient setting after hospital discharge; and 3 additional unscheduled study visits should the patient be readmitted for respiratory reasons during study participation (i.e. first readmission only).

  • 3 study visits will be scheduled during the hospitalization period of the index acute exacerbation:

    • visit 1: within 48h of hospital admission, study inclusion (Day 1)
    • visit 2: at 72h after study inclusion (Day 3)
    • visit 3: at hospital discharge, at investigator's discretion (Day X)
  • 3 study visits will be scheduled during the outpatient setting:

    • visit 4: at 3 months after study inclusion (Day 90)
    • visit 5: at 6 months after study inclusion (Day 180)
    • visit 6: at 12 months after study inclusion (Day 365)
  • The first hospital readmission for respiratory reasons during the patient's study participation will undergo the same testing schedule as mandated during the hospitalization period of the index event:

    • unscheduled visit 1: within 48h of first hospital readmission
    • unscheduled visit 2: within 72h of first hospital readmission
    • unscheduled visit 3: at hospital discharge for first hospital readmission

Resulting from CICERO's future lifecycles will be the continued expansion of the data- and bio-bank, both in cohort size and duration of follow-up.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease Exacerbation

Keywords

  • COPD
  • Exacerbation
  • Hospitalization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with COPD, hospitalized for an acute exacerbation

Eligibility criteria

Inclusion Criteria:

  • Age 18 years and older
  • Established diagnosis of by medical doctor (based on clinical history OR pulmonary function test with an /FVC \< 0.7)
  • Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD)
  • Inclusion within 48 hours post hospital admission
  • Voluntary written of the participant or his/her representative obtained prior to any study procedure

Exclusion Criteria:

  • Patients unwilling or unable to comply with study procedures
  • Patients not requiring treatment with systemic , antibiotics or both as a minimum therapy for the index AECOPD
  • Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Death from any cause

    Time frame: Will be assessed during 1 year, on visits 2-6

Secondary outcomes

  1. Step-up in hospital care for respiratory reasons

    A composite outcome measure defined as: 1. New hospitalization for respiratory reasons 2. Hospital care intensification from baseline (ie. within 24h from hospital admission) for respiratory reasons, including: * 2.1 Non-invasive respiratory therapy (oxygen by mask or nasal flow) * 2.2 Non-invasive respiratory therapy (oxygen by NIV or high flow) * 2.3 Invasive respiratory therapy (intubation and mechanical ventilation) * 2.4 Physiological support with inotropes

    Time frame: Will be assessed during 1 year, on visits 2-6

  2. Treatment intensification for respiratory reasons

    A composite outcome measure defined as: 1. Prolongation of systemic corticosteroids \>5 days administered for the index acute exacerbation or first readmission for respiratory reasons 2. Upgrade of antibiotics administered for the index exacerbation or first readmission for respiratory reasons 3. New course of systemic corticosteroids for respiratory reasons 4. New course of antibiotics for respiratory reasons

    Time frame: Will be assessed during 1 year, on visits 2-6

  3. Treatment failure

    A composite outcome measure defined as: 1. All-cause mortality 2. Step-up in hospital care for respiratory reasons 3. Treatment intensification for respiratory reasons

    Time frame: Will be assessed during 1 year, on visits 2-6

  4. Severe treatment failure

    As intensification of drug treatment regimens and treatment intensifications are country/region-specific and not always related to failure of disease control, severe treatment failure (STF) will be defined as the composite of: 1. All-cause mortality 2. Step-up in hospital care for respiratory reasons

    Time frame: Will be assessed during 1 year, on visits 2-6

  5. Readmission for a severe COPD exacerbation

    Readmission of the patient to the hospital for a severe COPD exacerbation

    Time frame: Will be assessed during 1 year, on visits 2-6

  6. New hospitalization for respiratory reasons

    New admission of the patient to the hospital for respiratory reasons

    Time frame: Will be assessed during 1 year, on visits 2-6

  7. Hospital care intensification for respiratory reasons

    A composite outcome measure defined as: 1. Non-invasive respiratory therapy (oxygen by mask or nasal flow) 2. Non-invasive respiratory therapy (oxygen by NIV or high flow) 3. Invasive respiratory therapy (intubation and mechanical ventilation) 4. Physiological support with inotropes

    Time frame: Will be assessed during 1 year, on visits 2-6

  8. Time to

    The time to the following outcomes will be measured: 1. All-cause mortality 2. First hospital readmission for respiratory reasons 3. Hospital care intensification for respiratory reasons 4. Treatment intensification for respiratory reasons 5. Treatment failure 6. Severe treatment failure

    Time frame: Will be assessed during 1 year, on visits 2-6

  9. Number of participants with a new or changed Do Not Resuscitate (DNR) code

    The implementation of a new or changed DNR code during study participation will be measured. * DNR 0: do not restrict therapy (i.e. explicit statement not to withhold any life-sustaining interventions) * DNR 1: do not resuscitate, further specified as: DNR 1a: No CPR DNR 1b: No CPR + no intubation + NIV to be considered * DNR 2: do not extend therapy (i.e. no CPR + no intubation + no NIV) * DNR 3: discontinue therapy (i.e. no CPR + no intubation + no NIV + withdrawal of current treatment°) Abbreviations: CPR, cardiopulmonary resuscitation; NIV, non-invasive ventilation; °, treatment of disabling symptoms to be prioritised, however, no life-prolonging interventions are to be continued

    Time frame: Will be assessed during 1 year, on visits 2-6

  10. Cumulative dose of systemic corticosteroids

    The total dose of systemic corticosteroids administered during study participation will be measured.

    Time frame: Will be assessed during 1 year, on visits 2-6

  11. Total days in hospital

    Total number of days spent in a hospital during study participation will be measured.

    Time frame: Will be assessed during 1 year, on visits 2-6

  12. Change in modified Medical Research Council (mMRC): a dyspnea scale

    The change in the following patient reported outcome measures (PROM) will be measured: modified Medical Research Council (mMRC): a dyspnea scale * scale: 0 to 4 * interpretation: higher scores indicate worse outcome

    Time frame: Will be assessed during 1 year, on visits 2-6

  13. Change in COPD Assessment Test (CAT): a COPD impact scale

    The change in the following patient reported outcome measures (PROM) will be measured: COPD Assessment Test (CAT): a COPD impact scale * scale: 0 to 40 * interpretation: higher scores indicate worse outcome

    Time frame: Will be assessed during 1 year, on visits 2-6

  14. Change in Patient Health Questionnaire-9 (PHQ-9): a depression scale

    The change in the following patient reported outcome measures (PROM) will be measured: Patient Health Questionnaire-9 (PHQ-9): a depression scale * scale: 0 to 29 * interpretation: higher scores indicate worse outcome

    Time frame: Will be assessed during 1 year, on visits 2-6

  15. Change in Generalized Anxiety Disorder-7 (GAD-7): an anxiety scale

    The change in the following patient reported outcome measures (PROM) will be measured: Generalized Anxiety Disorder-7 (GAD-7): a anxiety scale * scale: 0 to 21 * interpretation: higher scores indicate worse outcome

    Time frame: Will be assessed during 1 year, on visits 2-6

  16. Change in patient reported experience measure (PREM)

    The change in the following PREM will be measured: 1\. Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS): measuring patients' perceptions of their hospital experience -interpretation: higher scores indicate better outcome

    Time frame: Will be assessed during 1 year, on visits 2-6

  17. Change in comorbidities

    Changes in baseline comorbidies (ie. the appearance of new or worsening of existing) will be measured

    Time frame: Will be assessed during 1 year, on visits 2-6

  18. Change in biomarker Eotaxin-3 (CCL26)

    Eotaxin-3 is a small cytokine belonging to the CC chemokine family (called CCL26, Chemokine (C-C motif) ligand 26). Eotaxin-3 is chemotactic for eosinophils and basophils and elicits its effects by binding to the cell surface chemokine receptor CCR3.

    Time frame: Will be assessed during 1 year, on visits 2-6

  19. Change in biomarker IL-5

    Interleukin-5 (IL-5) acts on mature eosinophils, leading to proliferation, activation, differentiation, and survival; playing a critical role in the host immune response to infections.

    Time frame: Will be assessed during 1 year, on visits 2-6

  20. Change in biomarker IL-33

    Interleukin-33 (IL-33) is described as an inducer of type 2 immune responses, activating T helper 2 cells and mast cells.

    Time frame: Will be assessed during 1 year, on visits 2-6

  21. Change in biomarker MCP-4 (CCL13)

    Monocyte chemotactic protein 4 (MCP-4), also called CCL13, is a major chemo-attractant for eosinophils, basophils, monocytes and T lymphocytes

    Time frame: Will be assessed during 1 year, on visits 2-6

  22. Change in biomarker TARC4 (CCL17)

    Thymus and activation regulated chemokine (TARC), also known as CCL17, is a chemokine that induces chemotaxis of Type 2 T helper (Th2) cells.

    Time frame: Will be assessed during 1 year, on visits 2-6

  23. Change in biomarker IP-10 (CXCL10)

    Interferon gamma-induced protein 10 (IP-10 (CXCL10)) chemoattracts Th1 lymphocytes and monocytes, and inhibits cytokine-stimulated hematopoietic progenitor cell proliferation.

    Time frame: Will be assessed during 1 year, on visits 2-6

  24. Change in biomarker IL1A

    Interleukin 1 alpha (IL1A) stimulates the activity of genes involved in inflammation and immunity

    Time frame: Will be assessed during 1 year, on visits 2-6

  25. Change in biomarker IL-8

    Interleukin 8 (IL-8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells; which attracts and activates neutrophils in inflammatory regions

    Time frame: Will be assessed during 1 year, on visits 2-6

  26. Change in biomarker GM-CSF

    Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates proliferation and/or activation of monocytes, macrophages, neutrophils and eosinophils

    Time frame: Will be assessed during 1 year, on visits 2-6

07

Study locations

10 of 22 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 53 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 17, 2021
StartActual
Oct 25, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05008081
Lead sponsor
Wim Janssens
Collaborators
European Respiratory Society, AstraZeneca, Roche Pharma AG, GlaxoSmithKline
Responsible party
Wim Janssens (MD, PhD, KU Leuven) — Sponsor-investigator
First posted
Aug 17, 2021
Start date
Oct 25, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 22, 2026

Study contacts

Kristina Vermeersch, PhD
Contact
kristina.vermeersch@kuleuven.be
016342284 ext. +32
Amber Beersaerts
Contact
amber.beersaerts@kuleuven.be
016338928 ext. +32
Wim Janssens, MD, PhD
study chair · UZ/KU Leuven - Belgium
Mona Bafadhel, MD, PhD
study chair · King's College London - UK

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion